BBI becomes notch on Inverness' ever-growing acquisitions list
This article was originally published in Clinica
UK diagnostic test and reagents developer BBI has agreed to a £83.7m ($170.6m) takeover by its long-term partner Inverness Medical Innovations.
You may also be interested in...
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
No device-related warning letters were released by the US FDA the week of 31 March.